Rituximab Biosimilars Demonstrate Clinical Efficiency and Significant Cost Savings Among Patients With NHL and CLL
Key Takeaways:
- When comparing originator rituximab with its biosimilars, investigators found that both medications were associated with comparable health outcomes among patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
- The cost of rituximab biosimilars is significantly less than that of originator rituximab, making it the more cost-effective therapy option for NHL and CLL.
- The findings indicate rituximab biosimilars as effective, lower-cost treatment options compared to originator rituximab.
The purpose of biosimilars is to deliver comparable health outcomes at a lower cost than their originator drug, but real-world data on their effectiveness remains limited.
Researchers used data from the Carelon Research Healthcare Integrated Research Database to identify patients who were diagnosed with NHL and CLL between January 2018 and July 2024 and were treated with rituximab. They compared the clinical outcomes and costs between those treated with originator rituximab and those treated with its biosimilars.
Out of the 11 525 patients included in the study, 89.8% had NHL and 10.2% had CLL. Most patients, 61.8%, were treated with originator rituximab, and 38.2% were treated with a biosimilar.
Clinical and health outcomes, including follow-up duration, number of infusions, treatment duration, hospitalizations, and emergency visits, were similar between cohorts.
The only noteworthy difference between rituximab and its biosimilars was the cost of medication. Rituximab biosimilars cost significantly less than originator rituximab.
According to the authors, “Our findings demonstrate how biosimilar therapies in cancer can deliver similar clinical outcomes to originators, while generating meaningful cost savings for the U.S. healthcare system.”
Reference
Wangia Dixon R, Perkins K, Venkataraman M. Real-world resource use and cost in patients treated with originator or biosimilar rituximab in a large U.S. insurance claims database. J Clin Oncol. 2026;44(16):11159. doi:10.1200/JCO.2026.44.16_suppl.11159
